This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2023. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia. The webinar will last 90 minutes to accommodate audience questions.
Meanwhile, employment and salaries in non-retail settings—hospitals, physician offices, outpatient centers, and home healthcare—continued to grow. What’s ahead for 340B-eligible hospitals? Find out during The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. pharmacists.
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The webinar will be 90 minutes to accommodate audience questions.
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels Outlook 2023. Hospitals accounted for 87% of these skyrocketing 340B purchases. ICYMI, the Health Resources and Services Administration (HRSA) finally got tired of my Freedom of Information Act (FOIA) requests. billion (+$7.0
In this webinar, we will discuss the challenges CEOs face and their personal journey during this exciting stage of entrepreneurship. This webinar will cover: Key success factors. Panel discussions will be based around the recent publication The Digital Health Start-up Journey: From Series A to scaling up. Post-Series A challenges.
More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.
This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. We have found that the share of pharmacists who work at hospitals reached a new high. Click here to see the original post and comments from June 2021.
Speaking of PBMs, be sure to join me for my new live video webinar, PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding , on June 23, 2023, from 12:00 p.m. P.S. Join my more than 41,000 LinkedIn followers for daily links to neat stuff. (I to 1:30 p.m. Click here to learn more and sign up.
More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.
For example, during the height of the pandemic, NIHR’s integrated health research system was able to compare COVID-19 hospital caseloads to COVID-19 research activity in real time. This pharmaphorum webinar, held in association with the National Institute for Health Research (NIHR), will be held Wednesday 23rd March at 15:00 GMT / 16:00 CET.
If this clip whets your appetite for more, register to watch a replay of the full 90-minute video webinar from June. You can also check out our recent data deep dive: Hospitals Are Relying More on PBMs to Manage Manufacturers' 340B Contract Pharmacy Restrictions: DCI's 2024 Market Analysis. Click here if you can’t see the video below.
But primary care site protocols can’t just be cut and pasted from hospitals. In this pharmaphorum webinar, conducted in partnership with National Institute for Health Research (NIHR), we will hear from experts on how and why commercial researchers should be looking hard at primary care sites. The webinar will cover.
pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. Federal grantees are aligned primarily with the vertically intergated organizations' retail pharmacies, while hospitals rely on mail and specialty pharmacies. Fein, Ph.D., All rights reserved.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. During Friday’s webinar, I’ll be sharing my updated thoughts about the IRA’s impact on manufacturers, Part D plans, and patient behavior. Click here to see the original post and comments from September 2022.
This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. For updated data on hospital-owned specialty pharmacies, see Chapter 3 of DCI's new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. All rights reserved.
pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. Federal grantees are aligned primarily with the vertically intergated organizations' retail pharmacies, while hospitals rely on mail and specialty pharmacies. Fein, Ph.D., All rights reserved.
This pharmaphorum webinar, held in association with the National Institute for Health Research (NIHR), takes place on Thursday 12 th November, 14:00 GMT / 16:00 CET and will introduce the new NIHR National Patient Recruitment Centres and look at how the NPRCs will take a patient-centric approach to pharmaceutical research.
This pharmaphorum webinar, held in association with the National Institute for Health Research (NIHR), takes place on Wednesday 16 th December, 11:00 GMT / 12:00 CET and will look at how to navigate the compliance pathway to increase patient engagement with clinical trials. Gaining patient input on marketing and recruitment materials.
Find out during Drug Channel Implications of the Inflation Reduction Act , a new live video webinar with Adam J. Click here to learn more and reserve your spot at our April 5 webinar. P.S. Join my nearly 54,000 LinkedIn followers for daily links to neat stuff. What’s ahead for the drug channel? All rights reserved.
pharmacy industry—now act as contract pharmacies for the hospitals and other healthcare providers that participate in the 340B program. For more on 340B and the specialty market, join me for my upcoming July 29 live video webinar, Specialty Drugs Update: Trends, Controversies, and Outlook. Read on for details and my commentary below.
HEAL Health recently organised a webinar titled ‘Demystifying the NMC Guidelines Conundrum’ against the backdrop of the recent postponement of the National Medical Commission (NMC) guidelines. The task of mitigating costs associated with corporate hospitals and asserting our professional identity presents itself as an imperative.”
During next week’s Drug Channels Outlook 2025 live video webinar, he'll tell you what's ahead for the program that continues to defy gravity. I suspect similar reports are gonna be popular. And don't forget to put on your ruby slippers and hear from Doctor of Thinkology Adam J.
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers.
This week, Im rerunning some popular posts while I prepare for Fridays live video webinar: PBM Industry Update: Trends, Challenges, and Whats Ahead. Click here to see the original post from December 2024. Its time to pay attention to the money behind the 340B curtain.
The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription. to 1:30 p.m. Click here to learn more and sign up.
I want to share with you, dear reader, the strange but true tale of my recent foray into the wonderful world of hospital price transparency for routine lab services. Sometimes, a little knowledge can be a bad thing. to 1:30 p.m. CLICK HERE TO LEARN MORE AND SIGN UP.
However, developments in genomic medicine are making huge strides to improve this situation, and these will also be discussed during the webinar. IQVIA are partnering with MetabERN , G2M and EURODIS for this webinar. Dr Jeff Keefer is VP and head of the Pediatric and Rare Disease Centers of Excellence at IQVIA.
This week, I’m rerunning some popular posts while I prepare for today’s Drug Channels Outlook 2024 live video webinar. Hospitals accounted for 87% of 340B purchases for 2022. My topic #9 for 2024: The Battle Over 340B Gets Even Messier. Click here to see the original post from September 2023. billion —an astonishing $9.8 billion (+$2.6
This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. The video is excerpted from my recent Drug Channels Update: Buy-and-Bill Trends video webinar. Click here to see the original post and comments from October 2021.
oncologists, cardiologists, primary care providers) Location (hospital networks, private clinics, telehealth providers) Behavioral intent (HCPs researching a specific drug category or condition) With the right targeting, pharma brands can drive meaningful interactions rather than wasting ad spend on irrelevant clicks.
We have found that the share of pharmacists who work at hospitals reached a new high. What’s more, average base salaries for retail pharmacists have dropped, while salaries have risen for pharmacists employed by hospitals, physician offices, and other non-retail settings. . to 1:30 p.m. CLICK HERE TO LEARN MORE AND SIGN UP.
pharmaphorum’s Unlocking Health Data to Improve Oncology Outcomes webinar sought to answer these questions by analysing how existing NHS data can be used in innovative ways to make informed decisions about drug research, discovery and value. Cook said this will be done with the highest standards of patient data privacy and ethical approval.
And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar.
pharmaphorum’s Behavioural insights into haem/onc clinical decision making webinar, in association with Medscape, showed that this can negatively impact physicians’ confidence as they try and keep on top of information about an array of treatment options. Data from the US cited during the webinar showed a five-year survival rate of 34.2%
This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Drug Channels Outlook 2022. I want to share with you, dear reader, the strange but true tale of my recent foray into the wonderful world of hospital price transparency for routine lab services. See you soon!
A recent pharmaphorum webinar , held in partnership with Savana and BREATHE – the Health Data Research Hub for Respiratory Health, heard that RWE is also accelerating the development of new and innovative therapies and treatments to improve patient outcomes.
Join us on Tuesday 17th May at 14:00 BST / 15:00 CEST for this webinar, sponsored by IQVIA, where panellists will be discussing the use of rare disease-specific software solutions and how medical informatics methods can be used to reuse healthcare data for rare disease-relevant research. About the panel.
In a recent pharmaphorum webinar leaders from the NIHR’s five National Patient Recruitment Centres (NPRCs) outlined how they could bring cutting-edge therapies to greater numbers of UK patients. The centres will benefit from shared standard operating procedures and will collaborate with each other as they host trials, the webinar heard.
The video is excerpted from my recent Drug Channels Update: Buy-and-Bill Trends video webinar. To further help you understand this channel, I have also included a brief video to explain the buy-and-bill system. This post is adapted from Chapter 3 of our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.
Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.
Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.
Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.
In this webinar, sponsored by IQVIA, speakers from The Medical Informatics Group at the University Hospital Frankfurt and the Collaboration on Rare Diseases in Medical Informatics project, Germany will discuss the potential of medical informatics in rare disease research and treatment.
Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content